- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma
- Interventions
- prednisone, cyclophosphamide, etoposide, Vincristine, pralatrexate, laboratory biomarker analysis, comparative genomic hybridization, gene expression analysis, nucleic acid sequencing, mutation analysis, immunohistochemistry staining method, microarray analysis, RNA analysis
- Drug · Other · Genetic
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Stanford, California • Atlanta, Georgia + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 654
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neuroectodermal Tumor, Primitive, Neuroepithelioma, Osteosarcoma, Sarcoma, Sarcoma, Ewing's
- Interventions
- vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1986 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Thrombocytopenia
- Interventions
- filgrastim, vitamin E, busulfan, cytarabine, etoposide, fludarabine phosphate, isotretinoin, topotecan hydrochloride, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Dietary Supplement · Drug + 1 more
- Lead sponsor
- Drexel University College of Medicine
- Other
- Eligibility
- 19 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Solid Tumor
- Interventions
- Sirolimus, Cyclophosphamide, Etoposide, Celecoxib
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Radiation Therapy, Carboplatin, Cisplatin, Crizotinib, Erlotinib, Etoposide, Paclitaxel
- Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 137 more
- Conditions
- Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
- Interventions
- Bortezomib, Carboplatin, Etoposide, Ifosfamide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Germ Cell Cancer
- Interventions
- Olaparib, Gemcitabine, Docetaxel, Carboplatin, Etoposide, Autologous Stem-Cell Transplant (ASCT)
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ovarian Cancer
- Interventions
- Topotecan and VP16
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells, Melphalan, Peripheral Blood Stem Cell Transplantation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2036
- U.S. locations
- 4
- States / cities
- La Jolla, California • Sacramento, California • San Francisco, California + 1 more
- Conditions
- Recurrent or Refractory Pediatric Ependymoma
- Interventions
- erlotinib, etoposide
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Orange, California + 14 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Plerixafor, Mitoxantrone, Etoposide, Cytarabine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Carcinoma, Small Cell Lung
- Interventions
- RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide
- Drug
- Lead sponsor
- EpicentRx, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Westwood, Kansas
- Conditions
- Lung Cancer
- Interventions
- Surgery, Chest Irradiation, Cisplatin, Etoposide, Prophylactic Cranial Irradiation
- Procedure · Radiation · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Roniciclib (BAY1000394), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- Boca Raton, Florida • Port Saint Lucie, Florida • St Louis, Missouri + 4 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Bevacizumab and Etoposide
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Extensive-Stage Small Cell Lung Cancer
- Interventions
- sunitinib
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm
- Interventions
- etoposide phosphate, melphalan, topotecan, Autologous Stem Cell Rescue
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 15 Years to 69 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma
- Interventions
- vincristine sulfate, irinotecan hydrochloride, cyclophosphamide, doxorubicin hydrochloride, ifosfamide, etoposide, tirapazamine, filgrastim, sargramostim, pharmacological study, pharmacogenomic studies, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 20 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
- Interventions
- bortezomib, mitoxantrone hydrochloride, etoposide, cytarabine, flow cytometry
- Drug · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Interventions
- Bleomycin Sulfate, Cisplatin, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Involved-Field Radiation Therapy, Prednisone, Vincristine Sulfate Liposome
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 1,734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 153
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Pembrolizumab, MK-4830, Boserolimab, Lenvatinib, Etoposide, Cisplatin, Carboplatin
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 14
- States / cities
- Gilbert, Arizona • Aurora, Colorado • Atlanta, Georgia + 10 more
- Conditions
- ALL, Burkitt's Lymphoma, Lymphoblastic Leukemia, CML
- Interventions
- Rapamycin, High dose etoposide and cytarabine (HiVAC)
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, L3 Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma
- Interventions
- ifosfamide, etoposide, rituximab, carboplatin, filgrastim, methotrexate, cytarabine, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Small-Cell Lung Cancer
- Interventions
- Everolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 5
- States / cities
- Fayetteville, Arkansas • Aurora, Colorado • Boston, Massachusetts + 2 more